Liquid biopsy: A potential and promising diagnostic tool for advanced stage non-small cell lung cancer patients

DC Doval, R Deshpande, B Dhabhar, KG Babu, K Prabhash, R Chopra, PV Sripada, C Deshmukh, M Suryavanshi

Indian Journal of Cancer 2017 54(5):25-30

More than 50% of non-small cell lung cancer (NSCLC) cases harbor an actionable mutation, and molecular testing at different intervals can help in personalized and targeted treatment. Core tissue biopsy and needle biopsy done at the time of diagnosis/disease progression are interventional, time-consuming and can affect the patients adversely. Noninterventional biomarker testing by liquid biopsy promises to revolutionize advanced stage cancer screening. The present report was formulated based on an expert panel meeting of renowned oncologists who gave their opinions for minimally invasive liquid biopsy to detect targetable molecular biomarkers in advanced NSCLC cases. An exhaustive literature search was done to support their recommendations. Clinical utility of minimally invasive liquid biopsy, for detection of molecular biomarkers in advanced stage NSCLC patients, was broadly discussed by the key opinion leaders.

http://ift.tt/2ClOiZe